{"id":"W3088154109","doi":"10.1016/j.annonc.2020.08.519","title":"408P A prospective controlled trial of the efficacy of uracil and tegafur/leucovorin for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Sierra Oncology; Foundation Medicine; Chugai Pharmaceutical; Pfizer Japan; Novartis Pharma; Genentech; Eli Lilly and Company; Ono Pharmaceutical; Yakult Honsha; Daiichi Sankyo Europe; Servier; European Society for Medical Oncology; FibroGen; Astellas Pharma; Les Laboratories Pierre Fabre; Astellas Foundation for Research on Metabolic Disorders; Taiho Pharmaceutical; BeiGene; Sanofi; Instituto de Salud Carlos III; Amgen; Pfizer; Bristol-Myers Squibb; INCLIVA Instituto de Investigación Sanitaria; GlaxoSmithKline","keywords":"Medicine; Hazard ratio; Internal medicine; Randomization; Tegafur; Clinical endpoint; Propensity score matching; Gastroenterology; Surgery; Colorectal cancer; Confidence interval; Randomized controlled trial; Regimen; Chemotherapy; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002822045,0.001241545,0.002383548,0.000325804,0.0004558649,0.001024124,0.0006552903,0.00193725,0.007304921],"category_scores_gemma":[0.003782249,0.0006648004,0.003909325,0.000610006,0.0008514022,0.0009344772,0.000488462,0.002552828,0.0008238986],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005420581,"about_ca_system_score_gemma":0.001093034,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001463999,"about_ca_topic_score_gemma":0.001777502,"domain_scores_codex":[0.9978868,0.001301036,0.0001297878,0.0004236567,0.0001149268,0.0001437952],"domain_scores_gemma":[0.9984478,0.00049944,0.0003836946,0.0002733184,0.00009546608,0.0003002918],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9864643,0.000699732,0.002901935,0.0002039668,0.003172029,0.0000235293,0.00001198414,0.000138842,0.0008458344,0.000089785,0.0004492471,0.004998842],"study_design_scores_gemma":[0.9421245,0.0393846,0.01238047,0.00004934907,0.003808032,0.00004152586,0.00001594647,0.0008151592,0.0003558885,0.0003155079,0.0006827421,0.00002623705],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9811196,0.005414356,0.002043635,0.001139146,0.0009837733,0.002949285,0.003382856,0.0001492244,0.002818124],"genre_scores_gemma":[0.9906799,0.0009223321,0.001324083,0.00107943,0.0003967366,0.001486607,0.001919021,0.00002159299,0.002170326],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007304921,"threshold_uncertainty_score":0.02443737,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2526387887178259,"score_gpt":0.4609450428407273,"score_spread":0.2083062541229014,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}